Norges Bank Invests $2.53 Million in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Norges Bank bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,461,120 shares of the company's stock, valued at approximately $2,528,000. Norges Bank owned 0.71% of Taysha Gene Therapies at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its stake in shares of Taysha Gene Therapies by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after acquiring an additional 11,390 shares during the period. Privium Fund Management B.V. raised its holdings in shares of Taysha Gene Therapies by 12.4% during the fourth quarter. Privium Fund Management B.V. now owns 134,900 shares of the company's stock worth $233,000 after acquiring an additional 14,900 shares during the period. Cibc World Markets Corp acquired a new position in shares of Taysha Gene Therapies during the fourth quarter worth about $28,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $31,000. Finally, AXQ Capital LP bought a new stake in Taysha Gene Therapies during the 4th quarter worth about $39,000. Institutional investors and hedge funds own 77.70% of the company's stock.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA traded down $0.04 during mid-day trading on Thursday, hitting $1.15. The company had a trading volume of 251,115 shares, compared to its average volume of 2,059,906. The stock's 50-day moving average price is $1.56 and its 200-day moving average price is $1.82. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies, Inc. has a 1 year low of $1.05 and a 1 year high of $4.32. The company has a market capitalization of $234.73 million, a price-to-earnings ratio of 1.82 and a beta of 0.96.

Remove Ads

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The company had revenue of $2.02 million for the quarter, compared to analysts' expectations of $2.05 million. On average, sell-side analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.